Key Findings From Recent Trials

Are you trying to work out whether Androxal is a real treatment option, or just another name that keeps popping up on forums?

The short answer is that enclomifene trial data looked encouraging for male secondary hypogonadism, but the medicine never made it into routine use.

In studies from the trial era, Androxal was investigated as an oral SERM, usually at 12.5 mg or 25 mg once daily.

The main signal was straightforward: endogenous testosterone rose, while LH and FSH were stimulated, which fits a strategy of preserving testicular function rather than replacing testosterone from outside.

That distinction matters for men who want to protect fertility, because testosterone replacement therapy can suppress sperm production.

Even so, the programme stopped short of approval.

The FDA did not approve it, and the EMA refused marketing authorisation in 2018 for secondary hypogonadism.

As of 2025, there is no ATC code assigned and it remains experimental.

Trial reports generally centred on men with secondary hypogonadism, not on broad testosterone deficiency across all causes.

That means the evidence base is narrower than many online discussions suggest.

For a patient asking in a Friday evening consultation, “Will this work like clomifene tablets but better?”, the honest answer is that the hormone response was promising, but the evidence never matured into a licensed medicine.

Safety findings were mixed in the usual way with a development programme that stopped early.

Common trial-reported issues included headache, nausea, hot flushes, mood changes and visual disturbance.

Long-term safety is still not properly defined, because the development pathway was discontinued before broad real-world use could be studied.

That is why clinicians remain cautious when comparing enclomifene with clomifene citrate or clomiphene citrate in male secondary hypogonadism.

Both clomifene and enclomifene sit in a similar pharmacological space, but Androxal itself never became a standard pharmacy medicine.

Basic Androxal Information

• INN (International Nonproprietary Name): Enclomifene, also written as enclomiphene.
• Brand names available in United Kingdom: Androxal® is not commercially available, and EnCyzix was only a tentative former name.
• ATC Code: No ATC code assigned.
• Forms & dosages: Investigational oral tablets, typically 12.5 mg or 25 mg.
• Manufacturers in United Kingdom: None licensed; Repros Therapeutics Inc. was the original developer in the USA.
• Registration status in United Kingdom: No MHRA approval and no authorised UK product.
• OTC / Rx classification: Prescription-only in investigational settings, and not OTC anywhere.
• Competitors / alternatives: Clomiphene citrate, tamoxifen and testosterone replacement therapy.

People often ask whether Androxal is “just clomifene” under another name.

It is related, because enclomifene is the active (E)-isomer of clomiphene, but it is not the same product and it never received legitimate UK pharmacy status.

There is no official UK pack information, no approved leaflet, and no standard NHS route for supply.

If a website offers enclomifene citrate as if it were a normal medicine, that should raise a red flag immediately.

Clinical Mechanism Of Action

How can a tablet raise testosterone without actually giving testosterone?

That is the basic attraction of Androxal.

Enclomifene was explored as an investigational medicine that tells the body to make its own testosterone rather than supplying it directly.

This is why it interested men worried about fertility, since preserving sperm production is often a priority in secondary hypogonadism.

By contrast, testosterone replacement therapy can ease symptoms but may reduce gonadotropin signalling and suppress sperm production.

Scientifically, enclomifene is the active (E)-isomer of clomiphene or clomifene.

It acts as a nonsteroidal SERM and as an oestrogen receptor antagonist at the hypothalamus.

Blocking oestrogen feedback increases LH and FSH release from the pituitary.

Those gonadotropins then stimulate the testes to produce more endogenous testosterone.

The pathway is neat, which is why endocrinologists and fertility specialists paid attention to it for male secondary hypogonadism.

Hypothalamus: reduced oestrogen signalling.

Pituitary: increased gonadotropin release.

Testes: increased endogenous testosterone synthesis.

For readers comparing oral SERM options, the mechanism of action sounds very similar to clomifene tablets, but the evidence base and regulatory status are not the same.

That difference matters more than brand familiarity.

Scope Of Approved And Off-Label Use

Is there any legitimate UK prescription route for Androxal?

No.

Enclomifene is not approved in the UK and has no legitimate prescription status here.

There is no MHRA-listed authorised Androxal product, no OTC route and no official UK packaging information because development stopped.

That leaves a grey-market gap.

Some compounding pharmacies and online sellers may advertise enclomifene citrate as a research chemical, but these are not regulated medicines.

In UK practice, clinicians are far more likely to consider licensed alternatives such as clomifene citrate off-label, or testosterone replacement therapy when appropriate.

NHS use is not standard because there is no approved product to prescribe in routine care.

Any use would sit outside normal prescribing and would require specialist oversight, usually in endocrinology or fertility medicine.

For patients browsing after hours, that can be confusing, especially when search results mix Androxal UK, clomifene and testosterone together.

It is worth being blunt: online availability does not make a product regulated, and research chemical labelling does not turn it into a licensed medicine.

In our online pharmacy, androxal is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

That kind of offer should be viewed carefully, because it does not change the underlying MHRA status or the absence of licensed UK approval.

Dosage Strategy

What dose was actually studied?

Based on trial data only, the typical oral dosage was 12.5 mg or 25 mg once daily.

Those are trial regimens, not licensed dosing instructions.

For male secondary hypogonadism, the studies used 12.5–25 mg orally once daily.

That was the main condition investigated.

There is no established dosing guidance for children, older adults or people with significant liver or kidney impairment.

No one should try to copy clomifene or clomiphene dosing and assume the same result will follow.

The two medicines are related, but they are not interchangeable in a way that supports casual dose swapping.

Nor should enclomifene dosing be extrapolated from testosterone replacement therapy, which works through a completely different hormonal pathway.

Clinical studies explored daily use for up to 6 months.

That is enough to see a hormonal signal, but not enough to settle long-term safety or long-term fertility outcomes.

For a man hoping to avoid injections and keep sperm production intact, an oral tablet sounds attractive.

Still, the dose question only makes sense after diagnosis is confirmed by a specialist and the treatment goal is clear.

Safety Protocols

What should stop someone using it?

There are clear contraindications, and they matter because the product never became a routine medicine with broad safety data.

Absolute contraindications include hypersensitivity to enclomifene or clomifene compounds, hormone-dependent tumours such as breast, uterine or prostate cancer, and pregnancy.

Pregnancy is not a use case for this medicine, and there is teratogenic risk.

Relative caution is sensible in severe hepatic or renal impairment, uncontrolled pituitary or ovarian disorders, and any history of thrombosis or embolism.

That last point is important because thromboembolic risk is something specialists take seriously when reviewing any SERM.

Common side effects were usually mild to moderate in trial reports.

These included headache, nausea, visual disturbances such as blurred vision or spots, hot flashes and mood changes.

Visual symptoms deserve prompt review rather than a “wait and see” approach.

In a specialist setting, monitoring would focus on symptoms, testosterone response and adverse effects.

If a patient reports sudden changes in vision or symptoms suggesting a clot, medical review should not be delayed.

That is the practical safety profile: promising hormonal effects, but not a medicine to treat casually or self-start from an unregulated source.

Interaction Mapping

Can you take it with food?

No formal food-interaction data are established, because the drug is not approved.

For practical purposes, the studied oral tablet format suggests that consistency in dosing time may matter more than any specific food effect.

The bigger concern is drug combinations.

Extra caution is sensible with other hormone-modifying medicines, especially testosterone replacement therapy or agents affecting the hypothalamic-pituitary-gonadal axis.

That includes any regimen that mixes oral SERM treatment with anabolic products, supplements marketed for testosterone boosting or compounded hormone stacks sold online.

In UK pharmacy practice, enclomifene should not be treated like a routine community pharmacy interaction check.

Because it is unlicensed, specialist pharmacology review is the safer default.

Patients often ask whether they can “just take it alongside TRT for balance”.

That sort of plan should not be improvised, because the hormonal logic can conflict with the goal of stimulating endogenous testosterone.

For that reason, interaction mapping here is about endocrine strategy as much as it is about classic drug-drug interactions.

Patient Experience Analysis

What do patients actually say about it?

There is no robust UK patient survey base for Androxal, because it never became a marketed medicine.

Most patient experience data come from trial reports and extrapolation from similar SERMs.

Online discussion tends to circle around fertility preservation, libido, testosterone levels and comparisons with clomifene or TRT.

That pattern is predictable.

Men with secondary hypogonadism often want symptom relief without sacrificing fertility, and an oral tablet can sound simpler than injections or gels.

Grey-market users sometimes describe the convenience of oral dosing.

But those comments are not the same as verified clinical evidence.

There is also a recurring concern about authenticity.

People worry whether the product really contains enclomifene, whether the dose is accurate and whether the seller is genuine.

That is a fair concern, especially when there is no legitimate online or pharmacy distribution as of 2025.

For many patients, the real comparison is not Androxal versus nothing.

It is Androxal versus clomifene citrate, tamoxifen or testosterone replacement therapy under medical supervision.

That is where fertility goals, diagnosis and access to licensed care should guide the decision.

Distribution And Pricing Landscape

Can you actually buy it through a normal UK pharmacy supply chain?

No, you cannot.

Androxal is not commercially available in the UK or elsewhere.

There are no licensed UK pack sizes and no legitimate pharmacy distribution.

The original developer was Repros Therapeutics, but there is no active branded market now.

Because the product was discontinued, there is no stable retail price to quote.

Any online pricing should be treated as non-standard and high risk, particularly if the seller is unregulated.

That applies whether the item is described as enclomifene, enclomifene citrate or a research chemical.

In practical terms, if a site has a neat price grid and promises fast shipment, that does not make the medicine licensed.

It usually means the opposite.

For patients in the UK, that leaves licensed alternatives as the sensible discussion point rather than chasing an unavailable brand name.

Alternative Options

What do UK clinicians usually consider instead?

The decision usually comes down to fertility goals, endocrine diagnosis and access to licensed treatment.

Clomifene citrate is the closest familiar alternative.

Clomid and Serophene are widely recognised brand names in infertility care, and clomifene citrate is commonly used off-label for male fertility support.

Tamoxifen is another SERM used in some specialist settings.

Testosterone replacement therapy is effective for symptom relief, and it comes in many forms such as injectable, gel and patch.

The trade-off is clear: TRT directly supplies exogenous testosterone, which can be the right answer for some men but is not ideal when fertility is a priority.

Androxal or enclomifene remains theoretically fertility-preserving, but it is unlicensed and unavailable.

Clomifene citrate has broader real-world use, but it is not identical.

For UK patients, the real question is usually not “How do I get Androxal?”

It is “Which specialist treatment fits my diagnosis and future fertility plans?”

Regulatory Status

Where does the regulator stand?

In the UK, there is no MHRA approval.

In the US, the FDA did not approve it and the New Drug Application was rejected.

In Europe, the EMA refused marketing authorisation in 2018 for secondary hypogonadism.

As of 2025, no country has active prescription or OTC status for enclomifene.

There is also no ATC code assigned.

So the classification remains experimental: a nonsteroidal SERM and investigational gonadotropin stimulant.

The regulatory takeaway is simple.

Any product marketed as Androxal in the UK should be treated as unauthorised unless proven otherwise.

That is especially important when online sellers present the product as though it were a standard clomifene tablet or a mainstream testosterone treatment.

It is not.

Consolidated FAQ

Is Androxal available in the UK? No, it is not approved and has no legitimate UK prescription status.

Is it the same as clomifene? It is the active isomer related to clomiphene or clomifene, but it is not the same product.

Does it help fertility? It was investigated in male secondary hypogonadism and for fertility-related hormone support, but it was never approved.

Can I buy it online? Any sale is unregulated and risky.

Is it OTC? No, nowhere.

What was the usual trial dose? 12.5 mg or 25 mg once daily.

People searching for Androxal UK often want a fertility-preserving way to lift testosterone without injections.

That is a reasonable goal, but the right answer still has to be based on licensed care and a confirmed endocrine diagnosis.

Visual Guide

A useful infographic for Androxal should keep the hormone pathway simple.

Start with the hypothalamus-pituitary-testis axis and show enclomifene blocking oestrogen feedback.

Then show LH and FSH rising, followed by increased endogenous testosterone production.

A comparison panel helps too.

One side can show enclomifene as an investigational oral tablet studied at 12.5 mg and 25 mg.

Another can show clomifene citrate as a more familiar SERM option.

The third panel can show TRT as direct testosterone replacement.

The clearest labels are usually the most effective:

Investigational only.

No UK approval.

Oral tablet studied at 12.5 mg and 25 mg.

Fertility-preserving concept.

A timeline can also show development, trial use and regulatory refusal.

Adding a warning icon for grey-market risk would reflect real purchasing concerns in the UK.

Storage And Transport

How should it be stored if someone is dealing with lawful research material?

Store at room temperature, between 15–30°C.

Keep it in the original packaging and protect it from moisture.

That is the standard handling advice for investigational oral tablets.

Transport guidance is more cautious, because there is no legitimate commercial supply to the public.

Any transport discussion should relate only to lawful, regulated research materials.

Do not rely on unverified online packaging or labelling.

Since no approved UK product exists, much of the patient-facing storage advice is theoretical rather than based on an everyday pharmacy product.

That is another sign that Androxal sits outside normal community pharmacy practice.

Guidelines For Proper Use

Should anyone self-medicate with it?

No.

Any use should be limited to formal research or carefully supervised specialist decision-making, because enclomifene is unapproved.

Do not self-medicate with grey-market enclomifene citrate.

Before any SERM strategy is considered, the diagnosis of secondary hypogonadism should be confirmed.

That sounds obvious, but it is often skipped in online conversations about testosterone levels.

If treatment is started in a specialist setting, benefit, side effects and fertility goals should be reassessed regularly.

For missed doses, take the dose as soon as remembered unless it is nearly time for the next one.

Do not double up.

For overdose, there is no specific antidote.

Supportive care is recommended.

Those are sensible safety rules, but they do not replace a proper prescription pathway.

The same goes for comparing enclomifene with clomifene tablets or TRT.

The right choice depends on diagnosis, fertility plans and specialist oversight, not on which product is easiest to find online.

Delivery Across United Kingdom